{
  "$schema": "folio-library-document/v1",
  "id": "10665-340190",
  "title": "Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring",
  "variant": "pdf",
  "pages": 84,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "I. \u0003Abbreviations and acronyms",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-i-abbreviations-and-acronyms"
    },
    {
      "level": 1,
      "title": "II. \u0003Definition of key terms",
      "number": null,
      "page": 8,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-ii-definition-of-key-terms"
    },
    {
      "level": 1,
      "title": "III. \u0003Acknowledgements",
      "number": null,
      "page": 10,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-iii-acknowledgements"
    },
    {
      "level": 1,
      "title": "V. \u0003Executive summary",
      "number": null,
      "page": 13,
      "pageLabel": "xi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-v-executive-summary"
    },
    {
      "level": 1,
      "title": "INTRODUCTION",
      "number": "1",
      "page": 16,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-1-introduction"
    },
    {
      "level": 2,
      "title": "\u0003Background and rationale",
      "number": "1.1",
      "page": 16,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-11-background-and-rationale"
    },
    {
      "level": 2,
      "title": "\u0003Objectives",
      "number": "1.2",
      "page": 18,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-12-objectives"
    },
    {
      "level": 2,
      "title": "\u0003Target audience",
      "number": "1.3",
      "page": 18,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-13-target-audience"
    },
    {
      "level": 2,
      "title": "\u0003Guiding principles",
      "number": "1.4",
      "page": 18,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-14-guiding-principles"
    },
    {
      "level": 2,
      "title": "\u0003Methods for developing the guidelines",
      "number": "1.5",
      "page": 19,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-15-methods-for-developing-the-guidelines"
    },
    {
      "level": 3,
      "title": "References",
      "number": null,
      "page": 20,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-references"
    },
    {
      "level": 1,
      "title": "CLINICAL GUIDELINES: ANTIRETROVIRAL DRUGS FOR HIV PREVENTION",
      "number": "2",
      "page": 21,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-2-clinical-guidelines-antiretroviral-drugs-for-h"
    },
    {
      "level": 2,
      "title": "\u0003The dapivirine vaginal ring",
      "number": "2.1",
      "page": 21,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-21-the-dapivirine-vaginal-ring"
    },
    {
      "level": 3,
      "title": "References",
      "number": null,
      "page": 30,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-references"
    },
    {
      "level": 1,
      "title": "CLINICAL GUIDELINES: DIAGNOSTICS AND TREATMENT MONITORING",
      "number": "3",
      "page": 34,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-3-clinical-guidelines-diagnostics-and-treatment"
    },
    {
      "level": 2,
      "title": "\u0003Point-of-care infant diagnosis",
      "number": "3.1",
      "page": 34,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-31-point-of-care-infant-diagnosis"
    },
    {
      "level": 2,
      "title": "\u0003Point-of-care viral load testing",
      "number": "3.2",
      "page": 40,
      "pageLabel": "25",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-32-point-of-care-viral-load-testing"
    },
    {
      "level": 2,
      "title": "\u0003Treatment monitoring algorithm",
      "number": "3.3",
      "page": 45,
      "pageLabel": "30",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-33-treatment-monitoring-algorithm"
    },
    {
      "level": 3,
      "title": "References",
      "number": null,
      "page": 54,
      "pageLabel": "39",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-references"
    },
    {
      "level": 1,
      "title": "4. CLINICAL GUIDELINES: TIMING OF ANTIRETROVIRAL THERAPY",
      "number": null,
      "page": 59,
      "pageLabel": "44",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-4-clinical-guidelines-timing-of-antiretroviral-t"
    },
    {
      "level": 2,
      "title": "\u0003Timing of ART for adults and children with TB",
      "number": "4.1",
      "page": 59,
      "pageLabel": "44",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-41-timing-of-art-for-adults-and-children-with-tb"
    },
    {
      "level": 3,
      "title": "References",
      "number": null,
      "page": 65,
      "pageLabel": "50",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-references"
    },
    {
      "level": 2,
      "title": "\u0003Updated clinical considerations for rapid ART initiation",
      "number": "4.2",
      "page": 67,
      "pageLabel": "52",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-42-updated-clinical-considerations-for-rapid-art"
    },
    {
      "level": 3,
      "title": "References",
      "number": null,
      "page": 70,
      "pageLabel": "55",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-references"
    },
    {
      "level": 1,
      "title": "DISSEMINATING, ADAPTING AND IMPLEMENTING THE GUIDELINES",
      "number": "5",
      "page": 72,
      "pageLabel": "57",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-5-disseminating-adapting-and-implementing-the-gu"
    },
    {
      "level": 1,
      "title": "Annexes",
      "number": null,
      "page": 73,
      "pageLabel": "58",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-annexes"
    },
    {
      "level": 2,
      "title": "Annex 1. Process for developing the clinical guideline",
      "number": null,
      "page": 73,
      "pageLabel": "58",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-annex-1-process-for-developing-the-clinical-guid"
    },
    {
      "level": 3,
      "title": "Annex 2. Simplified infant diagnosis algorithm",
      "number": null,
      "page": 82,
      "pageLabel": "67",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-annex-2-simplified-infant-diagnosis-algorithm"
    },
    {
      "level": 1,
      "title": "Box 1. \u0003Defining “substantial risk”",
      "number": null,
      "page": 22,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-box-1-defining-substantial-risk"
    },
    {
      "level": 1,
      "title": "Box 2. \u0003Priorities for point-of-care viral load testing",
      "number": null,
      "page": 45,
      "pageLabel": "30",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-box-2-priorities-for-point-of-care-viral-load-te"
    },
    {
      "level": 1,
      "title": "Box 3. \u0003Implementation considerations for treatment monitoring of pregnant and breastfeeding women",
      "number": null,
      "page": 53,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-box-3-implementation-considerations-for-treatmen"
    },
    {
      "level": 1,
      "title": "Box 4. \u0003Importance of screening for signs and symptoms of meningitis",
      "number": null,
      "page": 61,
      "pageLabel": "46",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-box-4-importance-of-screening-for-signs-and-symp"
    },
    {
      "level": 1,
      "title": "Box 5. \u0003Clinical considerations for people living with HIV being evaluated for rapid ART initiation",
      "number": null,
      "page": 67,
      "pageLabel": "52",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-box-5-clinical-considerations-for-people-living"
    },
    {
      "level": 1,
      "title": "Table A2. Technical scoping meetings to inform the clinical guideline update",
      "number": null,
      "page": 76,
      "pageLabel": "61",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-table-a2-technical-scoping-meetings-to-inform-th"
    },
    {
      "level": 1,
      "title": "Table A3. Summary of PICO questions",
      "number": null,
      "page": 77,
      "pageLabel": "62",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-table-a3-summary-of-pico-questions"
    },
    {
      "level": 1,
      "title": "Table A4. Criteria for consideration in evidence-to-decision-making tables",
      "number": null,
      "page": 80,
      "pageLabel": "65",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-table-a4-criteria-for-consideration-in-evidence"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "A",
      "labelEnd": "v",
      "words": 861,
      "summary": {
        "text": "The title, copyright and licence pages and table of contents of WHO's March 2021 updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring, with ISBNs. The contents list the chapters, annexes, tables and figures, including the PICO questions and technical scoping meetings. It also gives the suggested citation and standard WHO disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antiretroviral initiation",
          "heading": false
        },
        {
          "term": "infant diagnosis",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "monitoring algorithm",
          "heading": false
        },
        {
          "term": "updated recommendations",
          "heading": false
        },
        {
          "term": "point-of-care viral",
          "heading": false
        },
        {
          "term": "mediation rules",
          "heading": false
        },
        {
          "term": "treatment monitoring",
          "heading": false
        }
      ],
      "extract": "UPDATED RECOMMENDATIONS ON HIV PREVENTION, INFANT DIAGNOSIS, ANTIRETROVIRAL INITIATION AND MONITORING GUIDELINES MARCH 2021 UPDATED RECOMMENDATIONS ON HIV PREVENTION, INFANT DIAGNOSIS, ANTIRETROVIRAL INITIATION AND MONITORING MARCH 2021 Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring: March 2021 ISBN 978-92-4-002223-2 (electronic version) ISBN 978-92-4-002224-9",
      "extractCut": true,
      "blocks": [
        "library/10665-340190/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-i-abbreviations-and-acronyms",
      "number": null,
      "title": "I. \u0003Abbreviations and acronyms",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 8,
      "labelStart": "v",
      "labelEnd": "vi",
      "words": 64,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the 2021 HIV guideline update.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inhibitor",
          "heading": false
        },
        {
          "term": "life-year",
          "heading": false
        },
        {
          "term": "immunodeficiency",
          "heading": false
        }
      ],
      "extract": "AIDS acquired immunodeficiency syndrome ART antiretroviral therapy ARV antiretroviral (drug) CI confidence interval COVID-19 coronavirus disease DALY disability-adjusted life-year DTG dolutegravir EFV efavirenz GRADE Grading of Recommendations Assessment, Development and Evaluation HIV human immunodeficiency virus NNRTI non-nucleoside reverse-transcriptase inhibitor PI protease inhibitor PICO population,",
      "extractCut": true
    },
    {
      "id": "sec-001-ii-definition-of-key-terms",
      "number": null,
      "title": "II. \u0003Definition of key terms",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 10,
      "labelStart": "vi",
      "labelEnd": "viii",
      "words": 975,
      "summary": {
        "text": "Defines key terms used in the 2021 HIV guidelines, starting with HIV types and acute infection. It sets age-group definitions for adults, adolescents, children and infants, and defines key and vulnerable populations. Further definitions cover terms such as serodiscordant couples and partners.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prevention refers",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "arv drugs",
          "heading": false
        },
        {
          "term": "accessing hiv",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "vulnerable populations",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        }
      ],
      "extract": "General HIV refers to the human immunodeficiency virus. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of HIV infections globally. Acute (HIV) infection is the period between a person being infected with HIV and HIV antibodies being detectable by a serological assay. Age groups and populations The following definitions for adults, adolescents, children and infants are used in",
      "extractCut": true
    },
    {
      "id": "sec-002-iii-acknowledgements",
      "number": null,
      "title": "III. \u0003Acknowledgements",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 13,
      "labelStart": "viii",
      "labelEnd": "xi",
      "words": 1008,
      "summary": {
        "text": "Acknowledges the many contributors to the guideline, starting with the GRADE methodologist and the co-chairs and members of the Clinical Guideline Development Group from many countries. It goes on to name other reviewers, partners and WHO staff. It ends by naming PEPFAR, the US CDC, USAID, Unitaid and the Bill & Melinda Gates Foundation as funders.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "bill melinda",
          "heading": false
        },
        {
          "term": "melinda gates",
          "heading": false
        },
        {
          "term": "regional office",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "kevin moody",
          "heading": false
        },
        {
          "term": "london school",
          "heading": false
        }
      ],
      "extract": "WHO gratefully acknowledges the contributions of many individuals and organizations to the development of this guideline. GRADE METHODOLOGIST Nandi Siegfried (independent consultant, South Africa). CLINICAL GUIDELINE DEVELOPMENT GROUP Co-chairs: Diane Havlir (University of California at San Francisco, USA) and Ilesh Jani (Instituto Nacional de Saúde (National Institute of Health), Mozambique). Elaine Abrams (ICAP at",
      "extractCut": true
    },
    {
      "id": "sec-003-v-executive-summary",
      "number": null,
      "title": "V. \u0003Executive summary",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 16,
      "labelStart": "xi",
      "labelEnd": "1",
      "words": 1017,
      "summary": {
        "text": "The executive summary identifies the audience as national HIV programme managers, people living with HIV, health-care providers and policy-makers in low- and middle-income countries. It explains that the update followed WHO Guidelines Review Committee procedures and the GRADE approach. It sets out the public health rationale and introduces a summary table of the new recommendations, the revised monitoring algorithm and clinical considerations for rapid ART initiation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "initiating art",
          "heading": false
        },
        {
          "term": "updated recommendations",
          "heading": false
        },
        {
          "term": "art among",
          "heading": false
        },
        {
          "term": "rapid art",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "initiating treatment",
          "heading": false
        }
      ],
      "extract": "Audience The primary audience for this guideline is national HIV programme managers, people living with HIV, health-care providers and policy-makers in low- and middle-income countries. This guideline update will be a useful resource for clinicians and should help to shape the priorities of policy-makers in development agencies, international organizations, nongovernmental organizations and other implementing",
      "extractCut": true
    },
    {
      "id": "sec-004-1-introduction",
      "number": "1",
      "title": "INTRODUCTION",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-005-11-background-and-rationale",
      "number": "1.1",
      "title": "\u0003Background and rationale",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 18,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 1222,
      "summary": {
        "text": "Gives the epidemiological background, citing 38 million people living with HIV and 1.7 million new infections in 2019, with rising incidence in eastern Europe, central Asia and other regions. It notes that the 2020 Fast-Track targets were missed despite falling AIDS deaths. It then explains why updated guidance was needed on prevention, infant diagnosis, viral load monitoring and timing of ART for people with TB symptoms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "people dying",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "receiving art",
          "heading": false
        },
        {
          "term": "rapid art",
          "heading": false
        },
        {
          "term": "load testing",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        }
      ],
      "extract": "HIV infection is a public health issue. In 2019, more than 38.0 million [31.6 million–44.6 million] people were living with HIV, and more than 1.7 million [1.2 million–2.2 million] people acquired HIV. Nearly 61% of the people newly infected with HIV live in sub-Saharan Africa. Between 2010 and 2019, the epidemic also continued to grow in eastern Europe and central Asia, with the number of people acquiring HIV",
      "extractCut": true
    },
    {
      "id": "sec-006-12-objectives",
      "number": "1.2",
      "title": "\u0003Objectives",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 49,
      "summary": {
        "text": "States that the guidelines aim to contribute to WHO's 13th General Programme of Work and the goal of ending AIDS by 2030.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "triple-billion",
          "heading": false
        },
        {
          "term": "goods",
          "heading": false
        },
        {
          "term": "global",
          "heading": false
        }
      ],
      "extract": "These guidelines are intended to contribute to the 13th WHO Global Programme of Work – Triple-Billion initiative – as part of the Global Public Health Goods 1.1.2 as well as the objective to meet targets set out in the Sustainable Development Goal 3 to end of AIDS by 2030.",
      "extractCut": false
    },
    {
      "id": "sec-007-13-target-audience",
      "number": "1.3",
      "title": "\u0003Target audience",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 109,
      "summary": {
        "text": "Lists the target audience of the guidelines, chiefly national HIV programme managers and policy-makers, as well as clinicians, laboratory managers, community organizations and funding agencies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "programme managers",
          "heading": false
        },
        {
          "term": "national hiv",
          "heading": false
        },
        {
          "term": "service providers",
          "heading": false
        },
        {
          "term": "health programmes",
          "heading": false
        }
      ],
      "extract": "The guidelines are primarily intended for use by national HIV programme managers and policy- makers. They will also be of interest to the following audiences: • national HIV treatment and prevention advisory boards; • national TB and HIV programme managers; • managers of maternal, newborn and child health programmes; • managers of sexual and reproductive health programmes; • clinicians and other health service",
      "extractCut": true
    },
    {
      "id": "sec-008-14-guiding-principles",
      "number": "1.4",
      "title": "\u0003Guiding principles",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 249,
      "summary": {
        "text": "Lists the guiding principles behind the guidelines, such as a public health approach to scaling up antiretroviral drugs and the involvement of people living with HIV. Others include strengthening wider health systems, protecting human rights and gender equity, and adapting to local context.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        },
        {
          "term": "principles",
          "heading": true
        },
        {
          "term": "public health",
          "heading": false
        },
        {
          "term": "continuum",
          "heading": false
        },
        {
          "term": "guidelines",
          "heading": false
        },
        {
          "term": "informed",
          "heading": false
        }
      ],
      "extract": "The following principles have informed the development of these guidelines and should guide the implementation of the recommendations. • The guidelines should contribute to and expedite the achievement of key global and national HIV goals for 2016–2021 (11), contribute to the new Global Programme of Work – Triple-Billion initiative – as part of the Global Public Health Goods 1.1.2 and to realizing the Sustainable",
      "extractCut": true
    },
    {
      "id": "sec-009-15-methods-for-developing-the-guidelines",
      "number": "1.5",
      "title": "\u0003Methods for developing the guidelines",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 289,
      "summary": {
        "text": "Summarises the methods used to develop the guideline, which links to earlier WHO HIV guidelines and followed Guidelines Review Committee procedures and GRADE. It describes how declarations of interest were managed and how systematic reviews and evidence-to-decision tables informed the recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "development group",
          "heading": false
        },
        {
          "term": "review group",
          "heading": false
        },
        {
          "term": "external review",
          "heading": false
        },
        {
          "term": "web annexes",
          "heading": false
        },
        {
          "term": "accordance",
          "heading": false
        },
        {
          "term": "recommendations",
          "heading": false
        },
        {
          "term": "declaration",
          "heading": false
        }
      ],
      "extract": "This publication is linked to the 2016 WHO consolidated guidelines (4) and to previous guidelines developed in 2017, 2018 and 2019. These are collectively being compiled into a single consolidated publication containing all relevant guidance. Annex 1 details the full methods for developing this guideline. In summary, this guideline update was developed in accordance with procedures established by the WHO Guidelines",
      "extractCut": true
    },
    {
      "id": "sec-010-references",
      "number": null,
      "title": "References",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 307,
      "summary": {
        "text": "A reference list for the introduction, citing UNAIDS data, UN political declarations and earlier WHO HIV guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "geneva",
          "heading": false
        },
        {
          "term": "unaids",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        }
      ],
      "extract": "1. UNAIDS data. Geneva: UNAIDS; 2020 (https://www.unaids.org/en/resources/ documents/2020/unaids-data, accessed 4 February 2021). 2. United Nations General Assembly. Political declaration on HIV and AIDS: intensifying our efforts to eliminate HIV and AIDS. New York: United Nations; 2011 (https://www.unaids. org/en/aboutunaids/unitednationsdeclarationsandgoals/2011highlevelmeetingonaids, accessed 4 February 2021). 3.",
      "extractCut": true
    },
    {
      "id": "sec-011-2-clinical-guidelines-antiretroviral-drugs-for-h",
      "number": "2",
      "title": "CLINICAL GUIDELINES: ANTIRETROVIRAL DRUGS FOR HIV PREVENTION",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 4,
      "summary": {
        "text": "A section divider heading for the clinical guidelines on antiretroviral drugs for HIV prevention.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "DRUGS FOR HIV PREVENTION",
      "extractCut": false
    },
    {
      "id": "sec-012-21-the-dapivirine-vaginal-ring",
      "number": "2.1",
      "title": "\u0003The dapivirine vaginal ring",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 554,
      "summary": {
        "text": "Presents the conditional recommendation that the dapivirine vaginal ring may be offered as an extra prevention choice for women at substantial HIV risk. It gives background on oral PrEP uptake since 2015 and describes the ring as a female-initiated silicone device releasing an NNRTI, and it notes that long-acting injectable cabotegravir was not yet assessed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaginal ring",
          "heading": true
        },
        {
          "term": "dapivirine vaginal",
          "heading": true
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "prep containing",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "containing tenofovir",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        }
      ],
      "extract": "Recommendation The dapivirine vaginal ring may be offered as an additional prevention choice for women at substantial riska of HIV infection as part of combination prevention approaches. (conditional recommendation; moderate-certainty evidence) a. \u0007Substantial risk of HIV infection is defined as HIV incidence greater than 3 per 100 person–years in the absence of PrEP (see Box 1). Background PrEP (pre-exposure",
      "extractCut": true
    },
    {
      "id": "sec-013-box-1-defining-substantial-risk",
      "number": null,
      "title": "Box 1. \u0003Defining “substantial risk”",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 30,
      "labelStart": "7",
      "labelEnd": "15",
      "words": 4195,
      "summary": {
        "text": "Defines substantial HIV risk as incidence above 3 per 100 person-years without PrEP and discusses how thresholds and risk assessment tools may vary. The section then covers evidence and considerations for the dapivirine vaginal ring, as the start and end of this cut block indicate. Its closing part discusses switching between or combining the ring and oral PrEP, the need for adherence, and unknowns about whether the ring adds new users or replaces oral PrEP. It ends with cost and cost-effectiveness, calling for further analysis using real-world data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaginal ring",
          "heading": false
        },
        {
          "term": "dapivirine vaginal",
          "heading": false
        },
        {
          "term": "ring study",
          "heading": false
        },
        {
          "term": "ring versus",
          "heading": false
        },
        {
          "term": "ring during",
          "heading": false
        },
        {
          "term": "ring compared",
          "heading": false
        },
        {
          "term": "ring products",
          "heading": false
        },
        {
          "term": "aspire found",
          "heading": false
        }
      ],
      "extract": "Substantial risk of HIV infection is provisionally defined as HIV incidence greater than 3 per 100 person-years in the absence of PrEP. HIV incidence greater than 3 per 100 person-years has been identified among men who have sex with men, transgender women and heterosexual men and women who have sexual partners with undiagnosed or untreated HIV infection. Individual risk varies within groups at substantial risk",
      "extractCut": true
    },
    {
      "id": "sec-014-references",
      "number": null,
      "title": "References",
      "level": 3,
      "pageStart": 30,
      "pageEnd": 34,
      "labelStart": "15",
      "labelEnd": "19",
      "words": 1756,
      "summary": {
        "text": "A reference list for the dapivirine vaginal ring section, citing PrEP trials, regulatory reviews and studies of ring use, acceptability and adherence among African women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dapivirine ring",
          "heading": false
        },
        {
          "term": "vaginal ring",
          "heading": false
        },
        {
          "term": "ring acceptability",
          "heading": false
        },
        {
          "term": "ring containing",
          "heading": false
        },
        {
          "term": "ring during",
          "heading": false
        },
        {
          "term": "der straten",
          "heading": false
        },
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "van niekerk",
          "heading": false
        }
      ],
      "extract": "1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973. 2. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://www.who.int/hiv/pub/guidelines/ earlyrelease-arv/en, accessed 4 February 2021). 3. UNAIDS",
      "extractCut": true
    },
    {
      "id": "sec-015-3-clinical-guidelines-diagnostics-and-treatment",
      "number": "3",
      "title": "CLINICAL GUIDELINES: DIAGNOSTICS AND TREATMENT MONITORING",
      "level": 1,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 2,
      "summary": {
        "text": "A section divider heading for the clinical guidelines on diagnostics and treatment monitoring.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "TREATMENT MONITORING",
      "extractCut": false
    },
    {
      "id": "sec-016-31-point-of-care-infant-diagnosis",
      "number": "3.1",
      "title": "\u0003Point-of-care infant diagnosis",
      "level": 2,
      "pageStart": 34,
      "pageEnd": 40,
      "labelStart": "19",
      "labelEnd": "25",
      "words": 3053,
      "summary": {
        "text": "Presents the strong recommendation to use point-of-care nucleic acid testing to diagnose HIV in infants and children under 18 months. It explains the need, citing low early infant testing coverage, long laboratory turnaround times and high mortality among untreated infants. The later part of this cut block covers implementation, such as integrating point-of-care tools into laboratory networks, training and same-day linkage to care. It ends with research gaps, including quality assurance and a possible dual-use test for diagnosis and viral load.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care infant",
          "heading": true
        },
        {
          "term": "infant diagnosis",
          "heading": true
        },
        {
          "term": "same-day point-of-care",
          "heading": false
        },
        {
          "term": "point-of-care testing",
          "heading": false
        },
        {
          "term": "point-of-care technologies",
          "heading": false
        },
        {
          "term": "near point-of-care",
          "heading": false
        },
        {
          "term": "implementing point-of-care",
          "heading": false
        },
        {
          "term": "laboratory-based testing",
          "heading": false
        }
      ],
      "extract": "Recommendation Point-of-care nucleic acid testing should be used to diagnose HIV among infants and children younger than 18 months of age. (strong recommendation; high-certainty evidence) Background Although significant recent investments in improving the diagnostic networks, centralized laboratories and sample collection networks have been made in most high-burden settings, clear improvements in access to infant",
      "extractCut": true
    },
    {
      "id": "sec-017-32-point-of-care-viral-load-testing",
      "number": "3.2",
      "title": "\u0003Point-of-care viral load testing",
      "level": 2,
      "pageStart": 40,
      "pageEnd": 45,
      "labelStart": "25",
      "labelEnd": "30",
      "words": 2440,
      "summary": {
        "text": "Presents the conditional recommendation that point-of-care viral load testing may be used to monitor people receiving ART. It describes the growth of viral load testing since 2016 and remaining barriers, and introduces new point-of-care technologies giving results within one to two hours. Implementation considerations include fitting the technology within the treatment monitoring algorithm, integrated laboratory networks and setting patient priorities given limited capacity. It notes that rapid results may help prevent drug resistance, especially in children and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care viral",
          "heading": true
        },
        {
          "term": "viral load",
          "heading": true
        },
        {
          "term": "point-of-care testing",
          "heading": true
        },
        {
          "term": "point-of-care technologies",
          "heading": false
        },
        {
          "term": "standard-of-care testing",
          "heading": false
        },
        {
          "term": "point-of-care test",
          "heading": false
        },
        {
          "term": "preferred point-of-care",
          "heading": false
        },
        {
          "term": "compared point-of-care",
          "heading": false
        }
      ],
      "extract": "Recommendation Point-of-care viral load may be used to monitor treatment among people living with HIV receiving ART. (conditional recommendation; moderate-certainty evidence) Background In 2016, viral load testing was strongly recommended as the preferred approach to monitor treatment among people living with HIV, with the associated development of a treatment monitoring algorithm to identify potential adherence",
      "extractCut": true
    },
    {
      "id": "sec-018-box-2-priorities-for-point-of-care-viral-load-te",
      "number": null,
      "title": "Box 2. \u0003Priorities for point-of-care viral load testing",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 46,
      "labelStart": "30",
      "labelEnd": "31",
      "words": 384,
      "summary": {
        "text": "Box 2 lists priority groups for point-of-care viral load testing, such as pregnant and breastfeeding women, children and people with suspected treatment failure, and stresses training, quality assurance and treatment literacy. It ends with research gaps on optimizing implementation and a single test for diagnosis and viral load.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral load",
          "heading": true
        },
        {
          "term": "point-of-care viral",
          "heading": true
        },
        {
          "term": "load testing",
          "heading": true
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "research gaps",
          "heading": false
        },
        {
          "term": "further research",
          "heading": false
        },
        {
          "term": "implementation research",
          "heading": false
        },
        {
          "term": "quality assurance",
          "heading": false
        }
      ],
      "extract": "Point-of-care viral load testing should be given priority for the following populations: • Pregnant and breastfeeding women • Infants, children and adolescents • People requiring a repeat viral load after a first elevated viral load • People for whom treatment failure is suspected • People presenting sick, living with advanced HIV disease or having a known opportunistic infection (TB, cryptococcal infection, etc.) •",
      "extractCut": true
    },
    {
      "id": "sec-019-33-treatment-monitoring-algorithm",
      "number": "3.3",
      "title": "\u0003Treatment monitoring algorithm",
      "level": 2,
      "pageStart": 46,
      "pageEnd": 53,
      "labelStart": "31",
      "labelEnd": "38",
      "words": 3262,
      "summary": {
        "text": "Explains the updated treatment monitoring algorithm in WHO's HIV guidance, noting that rapid ART initiation, the move from efavirenz-based regimens to dolutegravir and rising pretreatment NNRTI resistance have changed the context since the 2016 viral load algorithm. It reviews four questions: when to do the first viral load test, when to repeat it after an elevated result, whether to switch NNRTI-based regimens after a single test, and what threshold defines treatment failure. Supporting evidence is set out for each consideration. The section ends with research gaps, including the clinical relevance of low-level viraemia on dolutegravir and monitoring needs for children, adolescents and pregnant and breastfeeding women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-level viraemia",
          "heading": false
        },
        {
          "term": "nnrti-based regimens",
          "heading": false
        },
        {
          "term": "nnrti-based art",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "load copies",
          "heading": false
        },
        {
          "term": "receiving nnrti-based",
          "heading": false
        },
        {
          "term": "monitoring algorithm",
          "heading": true
        },
        {
          "term": "elevated viral",
          "heading": false
        }
      ],
      "extract": "Background Viral load testing was strongly recommended as the preferred approach to monitor treatment among people living with HIV in 2016, with the associated development of a treatment monitoring algorithm to try to identify those who need to switch to second-line treatment if drug resistance is suspected (6). Since the 2016 viral load algorithm was developed, ART programmes in low- and middle- income countries",
      "extractCut": true
    },
    {
      "id": "sec-020-box-3-implementation-considerations-for-treatmen",
      "number": null,
      "title": "Box 3. \u0003Implementation considerations for treatment monitoring of pregnant and breastfeeding women",
      "level": 1,
      "pageStart": 53,
      "pageEnd": 54,
      "labelStart": "38",
      "labelEnd": "39",
      "words": 466,
      "summary": {
        "text": "Box 3 sets out implementation considerations for viral load monitoring in pregnant and breastfeeding women, such as prioritizing same-day point-of-care testing and adherence counselling at every antenatal and postnatal visit. It specifies when to test according to the timing of ART initiation and what to do, including enhanced infant prophylaxis and infant testing, when viral load exceeds 1000 copies/ml.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "breastfeeding women",
          "heading": true
        },
        {
          "term": "pregnant women",
          "heading": true
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "load copies",
          "heading": false
        },
        {
          "term": "treatment monitoring",
          "heading": true
        },
        {
          "term": "load testing",
          "heading": false
        },
        {
          "term": "conduct viral",
          "heading": false
        },
        {
          "term": "load test",
          "heading": false
        }
      ],
      "extract": "of pregnant and breastfeeding women • Whenever possible, use same-day point-of-care testing for viral load testing of pregnant and breastfeeding women to expedite the return of results and clinical decision-making. If this is not available, viral load specimens and results for pregnant and breastfeeding women should be given priority across the laboratory referral process (including specimen collection, testing and",
      "extractCut": true
    },
    {
      "id": "sec-021-references",
      "number": null,
      "title": "References",
      "level": 3,
      "pageStart": 54,
      "pageEnd": 59,
      "labelStart": "39",
      "labelEnd": "44",
      "words": 2323,
      "summary": {
        "text": "A list of references for the chapters on infant diagnosis and treatment monitoring, citing mainly UNAIDS data, WHO guidelines and studies on point-of-care infant diagnosis and viral load testing, including dried blood spot samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care viral",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "point-of-care hiv",
          "heading": false
        },
        {
          "term": "point-of-care testing",
          "heading": false
        },
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "routine point-of-care",
          "heading": false
        },
        {
          "term": "infant hiv",
          "heading": false
        },
        {
          "term": "point-of-care assays",
          "heading": false
        }
      ],
      "extract": "1. AIDSInfo [online database]. Geneva: UNAIDS; 2020 (http://aidsinfo.unaids.org, accessed 4 February 2021). 2. Bourne DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R et al. Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS. 2009;23:101–6. 3. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al. Early antiretroviral therapy and mortality among HIV-infected",
      "extractCut": true
    },
    {
      "id": "sec-022-4-clinical-guidelines-timing-of-antiretroviral-t",
      "number": null,
      "title": "4. CLINICAL GUIDELINES: TIMING OF ANTIRETROVIRAL THERAPY",
      "level": 1,
      "pageStart": 59,
      "pageEnd": 59,
      "labelStart": "44",
      "labelEnd": "44",
      "words": 3,
      "summary": {
        "text": "A section heading for chapter 4 on clinical guidelines for the timing of antiretroviral therapy.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "OF ANTIRETROVIRAL THERAPY",
      "extractCut": false
    },
    {
      "id": "sec-023-41-timing-of-art-for-adults-and-children-with-tb",
      "number": "4.1",
      "title": "\u0003Timing of ART for adults and children with TB",
      "level": 2,
      "pageStart": 59,
      "pageEnd": 61,
      "labelStart": "44",
      "labelEnd": "46",
      "words": 1257,
      "summary": {
        "text": "Gives the recommendation that people living with HIV start ART as soon as possible within two weeks of starting TB treatment, whatever their CD4 count, except where meningitis is present. The background traces earlier WHO advice on ART timing during TB treatment and notes the lack of alignment with rapid ART guidance. Evidence summarized includes trials showing that immune reconstitution inflammatory syndrome was not more frequent with dolutegravir or raltegravir than with efavirenz.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art",
          "heading": true
        },
        {
          "term": "eight weeks",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "reconstitution inflammatory",
          "heading": false
        },
        {
          "term": "art initiated",
          "heading": false
        },
        {
          "term": "initiating art",
          "heading": false
        },
        {
          "term": "art regimens",
          "heading": false
        },
        {
          "term": "inflammatory syndrome",
          "heading": false
        }
      ],
      "extract": "Recommendation ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of CD4 count, among people living with HIV.a Adults and adolescents (strong recommendation, low- to moderate-certainty evidence) Children and infants (strong recommendation, very-low-certainty evidence) a. Except when signs and symptoms of meningitis are present. Background TB remains the leading cause of",
      "extractCut": true
    },
    {
      "id": "sec-024-box-4-importance-of-screening-for-signs-and-symp",
      "number": null,
      "title": "Box 4. \u0003Importance of screening for signs and symptoms of meningitis",
      "level": 1,
      "pageStart": 61,
      "pageEnd": 65,
      "labelStart": "46",
      "labelEnd": "50",
      "words": 1656,
      "summary": {
        "text": "Box 4 explains that ART should be delayed in people with cryptococcal or TB meningitis, for 4–6 weeks and at least four weeks respectively, because early treatment raises adverse events and mortality. The section then extends the earlier-ART recommendation to children by extrapolation from adult evidence, given the high risks of delay in young children. It closes with research gaps on newer ARVs in TB coinfection, corticosteroids to prevent immune reconstitution syndrome and multi-disease adherence support.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reconstitution inflammatory",
          "heading": false
        },
        {
          "term": "inflammatory syndrome",
          "heading": false
        },
        {
          "term": "immune reconstitution",
          "heading": false
        },
        {
          "term": "earlier art",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "initiating art",
          "heading": false
        },
        {
          "term": "syndrome among",
          "heading": false
        },
        {
          "term": "art start",
          "heading": false
        }
      ],
      "extract": "meningitis Among people living with HIV with TB meningitis or other forms of meningeal infection such as cryptococcus, earlier ART is associated with more severe adverse events and increased mortality with cryptococcal meningitis. For people living with HIV with TB meningitis, immediate ART is associated with more severe adverse events compared with initiating ART two months after the start of TB treatment.a • ART",
      "extractCut": true
    },
    {
      "id": "sec-025-references",
      "number": null,
      "title": "References",
      "level": 3,
      "pageStart": 65,
      "pageEnd": 67,
      "labelStart": "50",
      "labelEnd": "52",
      "words": 895,
      "summary": {
        "text": "A list of references for the section on ART timing in people with TB, citing WHO TB and HIV guidelines and trials of early versus delayed ART during TB treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "engl med",
          "heading": false
        },
        {
          "term": "tuberculosis therapy",
          "heading": false
        },
        {
          "term": "paradoxical tuberculosis-associated",
          "heading": false
        },
        {
          "term": "reconstitution inflammatory",
          "heading": false
        },
        {
          "term": "abdool karim",
          "heading": false
        },
        {
          "term": "inflammatory syndrome",
          "heading": false
        }
      ],
      "extract": "1. Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who. int/publications/i/item/9789240013131, accessed 4 February 2021). 2. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 4",
      "extractCut": true
    },
    {
      "id": "sec-026-42-updated-clinical-considerations-for-rapid-art",
      "number": "4.2",
      "title": "\u0003Updated clinical considerations for rapid ART initiation",
      "level": 2,
      "pageStart": 67,
      "pageEnd": 67,
      "labelStart": "52",
      "labelEnd": "52",
      "words": 141,
      "summary": {
        "text": "Reports that a systematic review on TB symptom criteria for same-day ART initiation found no studies directly addressing the question, so the Guideline Development Group chose to clarify clinical considerations rather than make a new recommendation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art initiation",
          "heading": true
        },
        {
          "term": "same-day art",
          "heading": false
        },
        {
          "term": "suggesting",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "development group",
          "heading": false
        }
      ],
      "extract": "A systematic review was conducted to address the applicability of a minimum set of TB exclusion criteria (signs and symptoms) to enable same-day ART initiation among people newly diagnosed with HIV. The review (see Web Annexes) (1) identified four studies that met the inclusion criteria, but none directly addressed the question. However, the review findings did indicate that same-day ART initiation for people with",
      "extractCut": true
    },
    {
      "id": "sec-027-box-5-clinical-considerations-for-people-living",
      "number": null,
      "title": "Box 5. \u0003Clinical considerations for people living with HIV being evaluated for rapid ART initiation",
      "level": 1,
      "pageStart": 67,
      "pageEnd": 70,
      "labelStart": "52",
      "labelEnd": "55",
      "words": 1704,
      "summary": {
        "text": "Box 5 revises rapid ART guidance so that people with signs of TB, other than meningitis, start ART while TB is rapidly investigated, with follow-up within seven days, whereas ART is delayed if TB or cryptococcal meningitis is suspected. The background notes that TB caused 30% of HIV-associated deaths in 2019 and that rapid ART initiation has been recommended since 2017. Research gaps include the effect of this approach on care outcomes and the role of prophylactic corticosteroids in preventing immune reconstitution syndrome.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art initiation",
          "heading": true
        },
        {
          "term": "rapid art",
          "heading": true
        },
        {
          "term": "people living",
          "heading": true
        },
        {
          "term": "same-day art",
          "heading": false
        },
        {
          "term": "reconstitution inflammatory",
          "heading": false
        },
        {
          "term": "initiate same-day",
          "heading": false
        },
        {
          "term": "inflammatory syndrome",
          "heading": false
        },
        {
          "term": "initiating art",
          "heading": false
        }
      ],
      "extract": "evaluated for rapid ART initiation The Guideline Development Group suggested the following update to existing guidance on rapid ART initiation (2): • previous clinical consideration: brief delay in ART initiation while investigating for TB symptoms; and • new clinical consideration: among people living with HIV with signs and symptoms suggesting TB, except for central nervous system disease (meningitis), initiate",
      "extractCut": true
    },
    {
      "id": "sec-028-references",
      "number": null,
      "title": "References",
      "level": 3,
      "pageStart": 70,
      "pageEnd": 72,
      "labelStart": "55",
      "labelEnd": "57",
      "words": 866,
      "summary": {
        "text": "A reference list for the rapid ART section, followed by short sections on how WHO will monitor uptake of the guidelines, potential barriers, and modular updating of the guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "same-day hiv",
          "heading": false
        },
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "same-day art",
          "heading": false
        },
        {
          "term": "rapit randomized",
          "heading": false
        },
        {
          "term": "plos med",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "initiating antiretroviral",
          "heading": false
        },
        {
          "term": "fox",
          "heading": false
        }
      ],
      "extract": "1. Burke R, Macpherson P, Rickman H, Singh S, Hosseinipour M, Wilkinson RJ et al. What tuberculosis symptoms preclude safe same-day ART initiation? [Abstract available in Web Annex C.1] 2. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/ advanced-HIV-disease/en, accessed 4 February 2021). 3.",
      "extractCut": true
    },
    {
      "id": "sec-029-5-disseminating-adapting-and-implementing-the-gu",
      "number": "5",
      "title": "DISSEMINATING, ADAPTING AND IMPLEMENTING THE GUIDELINES",
      "level": 1,
      "pageStart": 72,
      "pageEnd": 73,
      "labelStart": "57",
      "labelEnd": "58",
      "words": 7,
      "summary": {
        "text": "A section heading for disseminating, adapting and implementing the guidelines, with web links to a mobile app.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "IMPLEMENTING THE GUIDELINES 11 Weblinks: www.hivtx.org/iphone, www.hivtx.org/android",
      "extractCut": false
    },
    {
      "id": "sec-030-annexes",
      "number": null,
      "title": "Annexes",
      "level": 1,
      "pageStart": 73,
      "pageEnd": 73,
      "labelStart": "58",
      "labelEnd": "58",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-031-annex-1-process-for-developing-the-clinical-guid",
      "number": null,
      "title": "Annex 1. Process for developing the clinical guideline",
      "level": 2,
      "pageStart": 73,
      "pageEnd": 76,
      "labelStart": "58",
      "labelEnd": "61",
      "words": 760,
      "summary": {
        "text": "Annex 1 describes the background to developing this clinical guideline, explaining that it updates the 2016 consolidated ARV guidelines in a modular way. Table A1 maps guidance issued since 2016 to the chapters of the consolidated guidelines, and a figure shows the hub-and-spoke model of technical scoping meetings. It notes the new recommendations will be integrated into the 2021 consolidated guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "updated consolidated",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "consolidated hiv",
          "heading": false
        },
        {
          "term": "updated recommendations",
          "heading": false
        },
        {
          "term": "technical scoping",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "antiretroviral initiation",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        }
      ],
      "extract": "Background The WHO 2013 consolidated guidelines for antiretroviral therapy combined recommendations across the continuum of HIV care for the first time. This was updated in 2016. Since then, growing evidence in clinical and operational studies necessitated developing updated normative guidance. Several supplementary guidelines have been published with a modular approach to address the emerging evidence. Table A1",
      "extractCut": true
    },
    {
      "id": "sec-032-table-a2-technical-scoping-meetings-to-inform-th",
      "number": null,
      "title": "Table A2. Technical scoping meetings to inform the clinical guideline update",
      "level": 1,
      "pageStart": 76,
      "pageEnd": 77,
      "labelStart": "61",
      "labelEnd": "62",
      "words": 599,
      "summary": {
        "text": "Table A2 lists technical scoping meetings held between 2017 and 2020 that informed the guideline update, and the text describes the virtual Guideline Development Group meeting held in late 2020 because of COVID-19. It explains how seven systematic reviews and other evidence were summarized and rated using GRADE.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guideline",
          "heading": true
        },
        {
          "term": "undesirable effects",
          "heading": false
        },
        {
          "term": "desirable effects",
          "heading": false
        },
        {
          "term": "group meeting",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "scoping",
          "heading": true
        },
        {
          "term": "opportunistic infections",
          "heading": false
        }
      ],
      "extract": "guideline update Details of scoping meetings held Date HIV and TB scoping consultation 2019 HIV treatment transition and drug sequencing in the context of new antiretroviral drugs (at the Conference on Retroviruses and Opportunistic Infections): think tank https://www.who.int/hiv/pub/meetingreports/think-tank-HIVtreatment-croi2017/en 2017 Partners synergy meeting 2017 WHO Meeting on Treatment and Monitoring",
      "extractCut": true
    },
    {
      "id": "sec-033-table-a3-summary-of-pico-questions",
      "number": null,
      "title": "Table A3. Summary of PICO questions",
      "level": 1,
      "pageStart": 77,
      "pageEnd": 80,
      "labelStart": "62",
      "labelEnd": "65",
      "words": 1539,
      "summary": {
        "text": "Table A3 summarizes the methods of the systematic reviews behind each PICO question, including the dapivirine vaginal ring, point-of-care infant diagnosis and point-of-care viral load monitoring, with review leads, search dates and included studies. The text then describes how the virtual meeting was run, with a 60% voting threshold agreed but all recommendations reached by consensus. Evidence-to-decision tables were prepared in line with GRADE and discussed with a methodologist.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care infant",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "conference databases",
          "heading": false
        },
        {
          "term": "search dates",
          "heading": false
        },
        {
          "term": "databases searched",
          "heading": false
        },
        {
          "term": "controlled trials",
          "heading": false
        },
        {
          "term": "point-of-care testing",
          "heading": false
        },
        {
          "term": "pubmed medline",
          "heading": false
        }
      ],
      "extract": "PICO question Summary of systematic review methods PICO 1: Should the dapivirine vaginal ring be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches? Review type: Systematic review and meta-analysis Review lead: Medical University of South Carolina, USA Search dates: 1 January 2010 to 3 August 2020 Databases searched: PubMed, CINAHL",
      "extractCut": true
    },
    {
      "id": "sec-034-table-a4-criteria-for-consideration-in-evidence",
      "number": null,
      "title": "Table A4. Criteria for consideration in evidence-to-decision-making tables",
      "level": 1,
      "pageStart": 80,
      "pageEnd": 82,
      "labelStart": "65",
      "labelEnd": "67",
      "words": 781,
      "summary": {
        "text": "Table A4 defines the criteria used in evidence-to-decision tables, such as certainty of evidence, benefits and risks, values, costs, equity and acceptability. The text then describes how conflicts of interest of the External Review Group were managed and how the draft guidelines were peer reviewed in November 2020.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "guideline steering",
          "heading": false
        },
        {
          "term": "competing interest",
          "heading": false
        },
        {
          "term": "steering group",
          "heading": false
        },
        {
          "term": "group members",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "interest forms",
          "heading": false
        },
        {
          "term": "external review",
          "heading": false
        }
      ],
      "extract": "making tables Domain Rationale Certainty of the evidence This is an assessment of the degree of confidence in the estimate of the effect: that is, the likelihood that the effect will differ substantially from what the research found. “Differ substantially” means a large enough difference that it might affect a decision. Benefits and risks When a new recommendation is developed, desirable effects (benefits) need to",
      "extractCut": true
    },
    {
      "id": "sec-035-annex-2-simplified-infant-diagnosis-algorithm",
      "number": null,
      "title": "Annex 2. Simplified infant diagnosis algorithm",
      "level": 3,
      "pageStart": 82,
      "pageEnd": 84,
      "labelStart": "67",
      "labelEnd": "69",
      "words": 554,
      "summary": {
        "text": "Annex 2 presents a simplified algorithm for diagnosing HIV in exposed infants and children under 18 months, with key principles such as testing the mother, NAT at nine months and confirming any positive result. Notes explain birth testing, point-of-care NAT and retesting to avoid false positives, and the page ends with WHO HIV department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nucleic-acid testing",
          "heading": false
        },
        {
          "term": "repeat nat",
          "heading": false
        },
        {
          "term": "perform nucleic-acid",
          "heading": false
        },
        {
          "term": "nucleic-acid test",
          "heading": false
        },
        {
          "term": "previous nucleic-acid",
          "heading": false
        },
        {
          "term": "infant",
          "heading": true
        },
        {
          "term": "antibody testing",
          "heading": false
        },
        {
          "term": "infant child",
          "heading": false
        }
      ],
      "extract": "The key principles for establishing whether HIV- exposed infants and children younger than 18 months are infected with HIV in low- and middle- income countries are as follows. • Assess HIV exposure status by antibody testing the mother. • Perform nucleic-acid testing for any HIV- exposed child who presents outside the national infant testing algorithm with clinical symptoms, regardless of previous nucleic-acid test",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "hiv infant",
      "heading": false
    },
    {
      "term": "point-of-care hiv",
      "heading": false
    },
    {
      "term": "hiv viral",
      "heading": false
    },
    {
      "term": "hiv treatment",
      "heading": false
    },
    {
      "term": "art initiation",
      "heading": true
    },
    {
      "term": "hiv prevention",
      "heading": true
    },
    {
      "term": "hiv diagnosis",
      "heading": false
    },
    {
      "term": "same-day hiv",
      "heading": false
    },
    {
      "term": "hiv testing",
      "heading": false
    },
    {
      "term": "antiretroviral initiation",
      "heading": false
    },
    {
      "term": "hiv among",
      "heading": false
    },
    {
      "term": "hiv guidelines",
      "heading": true
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "A",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "B",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "3",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "4",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "5",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "7",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "9",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "11",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "13",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "15",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 31,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "17",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 35,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "21",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "23",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "25",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "27",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "29",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "30",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "31",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "33",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "35",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "36",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 52,
      "label": "37",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "38",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 54,
      "label": "39",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 55,
      "label": "40",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "41",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 57,
      "label": "42",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "43",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "44",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 60,
      "label": "45",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "46",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 62,
      "label": "47",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "48",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "49",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "50",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 66,
      "label": "51",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "52",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 68,
      "label": "53",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "54",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "55",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 71,
      "label": "56",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "57",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 73,
      "label": "58",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 74,
      "label": "59",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 75,
      "label": "60",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 76,
      "label": "61",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 77,
      "label": "62",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 78,
      "label": "63",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "64",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "65",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 81,
      "label": "66",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "67",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 83,
      "label": "68",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 84,
      "label": "69",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Treatment monitoring algorithm\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "A1",
      "title": "\u0007 \u0007Summary of key normative guidance released and ongoing since 2016,",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A2",
      "title": "Technical scoping meetings to inform the clinical guideline update\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A3",
      "title": "Summary of PICO questions\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A4",
      "title": "Criteria for consideration in evidence-to-decision-making tables\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "\u0007Diagnostic accuracy of alternative sample collection types (dried blood spot)",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3",
      "title": "\u0007\u0003Implementation considerations for treatment monitoring of pregnant and",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4",
      "title": "\u0003Importance of screening for signs and symptoms of meningitis\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "\u0003Defining “substantial risk”",
      "page": 22,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "\u0003Priorities for point-of-care viral load testing",
      "page": 45,
      "pageLabel": "30",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5",
      "title": "\u0003Clinical considerations for people living with HIV being",
      "page": 67,
      "pageLabel": "52",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p051",
      "file": "figures/vfig-p051.webp",
      "page": 51,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Fig 1, a treatment monitoring algorithm for HIV. Routine viral load monitoring (results by 6 months and 12 months after ART initiation, then yearly) sorts results into undetectable (≤50 copies/ml), >50 to ≤1000 copies/ml, or >1000 copies/ml. Undetectable results mean maintaining the ARV drug regimen; higher results lead to enhanced adherence counselling and repeat viral load testing after 3 months, after which the regimen is maintained, maintained with continued counselling and retesting (>50 to ≤1000), or switched to an appropriate regimen (>1000). People on NNRTI-based regimens with >1000 copies/ml are switched to an appropriate regimen.",
        "ar": "الشكل 1، خوارزمية رصد العلاج لفيروس العوز المناعي البشري. يصنف الرصد الروتيني للحمل الفيروسي (النتائج بحلول 6 أشهر و12 شهرًا بعد بدء العلاج بمضادات الفيروسات القهقرية، ثم سنويًا) النتائج إلى: غير قابل للكشف (≤50 نسخة/مل)، أو من >50 إلى ≤1000 نسخة/مل، أو >1000 نسخة/مل. تعني النتائج غير القابلة للكشف الاستمرار على نظام الأدوية المضادة للفيروسات القهقرية؛ وتؤدي النتائج الأعلى إلى مشورة معززة بشأن الالتزام وإعادة اختبار الحمل الفيروسي بعد 3 أشهر، ثم يُستمر على النظام، أو يُستمر عليه مع مواصلة المشورة وإعادة الاختبار (>50 إلى ≤1000)، أو يُغيَّر إلى نظام مناسب (>1000). ويُغيَّر نظام من يتلقون نظامًا قائمًا على NNRTI ولديهم >1000 نسخة/مل إلى نظام مناسب.",
        "zh": "图1，艾滋病毒治疗监测流程。常规病毒载量监测（在开始抗逆转录病毒治疗后6个月和12个月获得结果，此后每年一次）将结果分为：检测不到（≤50拷贝/毫升）、>50至≤1000拷贝/毫升、>1000拷贝/毫升。检测不到则维持抗逆转录病毒药物方案；较高的结果则进行强化依从性咨询，并在3个月后重复病毒载量检测，之后维持方案、维持方案并继续咨询和复检（>50至≤1000），或换用适当的方案（>1000）。使用以NNRTI为基础的方案且>1000拷贝/毫升者，换用适当的方案。",
        "es": "Figura 1, algoritmo de seguimiento del tratamiento del VIH. El seguimiento sistemático de la carga viral (resultados a los 6 y 12 meses tras el inicio del TAR y después anualmente) clasifica los resultados en indetectable (≤50 copias/ml), >50 a ≤1000 copias/ml o >1000 copias/ml. Un resultado indetectable supone mantener el régimen de ARV; los resultados más altos conducen a asesoramiento reforzado sobre la adherencia y a repetir la prueba de carga viral a los 3 meses, tras lo cual se mantiene el régimen, se mantiene con asesoramiento y nueva prueba (>50 a ≤1000) o se cambia a un régimen adecuado (>1000). A las personas con regímenes basados en INNTI y >1000 copias/ml se les cambia a un régimen adecuado.",
        "fr": "Figure 1, algorithme de suivi du traitement de l’infection à VIH. Le suivi systématique de la charge virale (résultats à 6 mois et 12 mois après le début du TAR, puis chaque année) classe les résultats en indétectable (≤50 copies/ml), >50 à ≤1000 copies/ml ou >1000 copies/ml. Un résultat indétectable signifie le maintien du schéma d’ARV ; des résultats plus élevés entraînent un conseil renforcé en matière d’observance et un nouveau test de charge virale après 3 mois, à l’issue duquel le schéma est maintenu, maintenu avec poursuite du conseil et nouveau test (>50 à ≤1000) ou remplacé par un schéma approprié (>1000). Les personnes sous schéma à base d’INNTI avec >1000 copies/ml passent à un schéma approprié.",
        "ru": "Рис. 1 — алгоритм мониторинга лечения ВИЧ-инфекции. Плановый мониторинг вирусной нагрузки (результаты через 6 и 12 месяцев после начала АРТ, затем ежегодно) распределяет результаты на неопределяемую (≤50 копий/мл), от >50 до ≤1000 копий/мл и >1000 копий/мл. При неопределяемой нагрузке схема АРВ-препаратов сохраняется; при более высоких значениях проводится усиленное консультирование по приверженности и повторное определение вирусной нагрузки через 3 месяца, после чего схему сохраняют, сохраняют с продолжением консультирования и повторным тестированием (>50 до ≤1000) или переходят на соответствующую схему (>1000). Лиц, получающих схемы на основе ННИОТ, при >1000 копий/мл переводят на соответствующую схему."
      },
      "state": "draft"
    },
    {
      "id": "img-p084-1",
      "file": "images/img-p084-1.webp",
      "page": 84,
      "narratives": {
        "en": "ISBN barcode for 9789240022232.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب ISBN 9789240022232.",
        "zh": "ISBN条形码：9789240022232。",
        "es": "Código de barras del ISBN 9789240022232.",
        "fr": "Code-barres ISBN 9789240022232.",
        "ru": "Штрихкод ISBN 9789240022232."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Diagnostic accuracy of alternative sample collection types (dried blood spot) or point of care with lower theoretical treatment failure thresholds",
      "pages": [
        50
      ],
      "columns": [
        {
          "titles": "Sensitivity"
        },
        {
          "titles": "Abbott 1-spotᵃ"
        },
        {
          "titles": "Abbott 2-spotᵃ"
        },
        {
          "titles": "Biocentric"
        },
        {
          "titles": "BioMerieuxᵇ"
        },
        {
          "titles": "Hologicᶜ"
        },
        {
          "titles": "Roche FVEᵈ"
        },
        {
          "titles": "Roche SPEXᵈ"
        },
        {
          "titles": "Siemens"
        },
        {
          "titles": "Cepheid"
        }
      ],
      "rows": [
        [
          "1000",
          "88 (50–98)",
          "93 (84–97)",
          "95 (71–99)",
          "83 (78–87)",
          "85 (44–98)",
          "95 (85–98)",
          "98 (96–99)",
          "91 (69–98)",
          "96 (95–97)"
        ],
        [
          "800",
          "92 (5–100)",
          "93 (83–97)",
          "99 (44–100)",
          "85 (80–89)",
          "93 (31–100)",
          "95 (87–98)",
          "99 (96–100)",
          "91 (75–97)",
          "97 (96–98)"
        ],
        [
          "600",
          "93 (0–100)",
          "93 (84–97)",
          "99 (60–100)",
          "89 (84–92)",
          "95 (28–100)",
          "94 (84–98)",
          "99 (96–100)",
          "93 (84–97)",
          "97 (96–98)"
        ],
        [
          "500",
          "93 (0–100)",
          "93 (84–97)",
          "98 (67–100)",
          "89 (85–92)",
          "95 (29–100)",
          "93 (82–98)",
          "99 (96–100)",
          "97 (66–100)",
          "97 (96–98)"
        ],
        [
          "400",
          "94 (0–100)",
          "92 (84–97)",
          "98 (60–100)",
          "90 (86–93)",
          "95 (28–100)",
          "92 (81–97)",
          "99 (95–100)",
          "97 (63–100)",
          "96 (95–97)"
        ],
        [
          "200",
          "97 (0–100)",
          "91 (83–95)",
          "98 (65–100)",
          "89 (84–93)",
          "95 (22–100)",
          "89 (76–96)",
          "99 (95–100)",
          "98 (72–100)",
          "95 (93–97)"
        ],
        [
          "Detectable",
          "93 (63–99)",
          "93 (76–98)",
          "98 (60–100)",
          "88 (75–95)",
          "75 (52–90)",
          "97 (58–100)",
          "99 (95–100)",
          "90 (84–94)",
          "93 (88–96)"
        ],
        [
          "Specificity",
          "Abbott 1-spotᵃ",
          "Abbott 2-spotᵃ",
          "Biocentric",
          "BioMerieuxᵇ",
          "Hologicᶜ",
          "Roche FVEᵈ",
          "Roche SPEXᵈ",
          "Siemens",
          "Cepheid"
        ],
        [
          "1000",
          "99 (68–100)",
          "91 (82–96)",
          "55 (35–74)",
          "95 (89–98)",
          "73 (31–94)",
          "94 (72–99)",
          "48 (23–75)",
          "88 (75–94)",
          "97 (93–98)"
        ],
        [
          "800",
          "99 (24–100)",
          "92 (83–96)",
          "38 (11–76)",
          "96 (91–98)",
          "72 (42–90)",
          "93 (65–99)",
          "38 (13–70)",
          "87 (68–95)",
          "97 (93–99)"
        ],
        [
          "600",
          "99 (12–100)",
          "93 (81–97)",
          "28 (6–71)",
          "95 (91–97)",
          "89 (50–99)",
          "93 (68–99)",
          "33 (12–65)",
          "79 (61–90)",
          "96 (92–98)"
        ],
        [
          "500",
          "99 (9–100)",
          "93 (82–98)",
          "24 (4–68)",
          "95 (91–98)",
          "89 (50–98)",
          "92 (68–98)",
          "30 (10–62)",
          "66 (31–89)",
          "95 (90–98)"
        ],
        [
          "400",
          "99 (8–100)",
          "93 (80–98)",
          "11 (1–73)",
          "96 (91–98)",
          "88 (48–98)",
          "92 (68–98)",
          "28 (9–60)",
          "65 (25–91)",
          "96 (93–98)"
        ],
        [
          "200",
          "99 (5–100)",
          "97 (92–99)",
          "15 (1–70)",
          "93 (89–95)",
          "81 (72–89)",
          "92 (71–98)",
          "25 (8–58)",
          "65 (26–90)",
          "98 (95–99)"
        ],
        [
          "Detectable",
          "93 (66–99)",
          "79 (8–99)",
          "19 (5–51)",
          "93 (90–96)",
          "87 (67–96)",
          "58 (6–97)",
          "4 (0–54)",
          "69 (41–88)",
          "81 (65–90)"
        ]
      ],
      "notes": "a. Abbott RealTime HIV-1 b. bioMerieux NucliSENS EasyQ HIV-1 v2.0 c. Hologic Aptima HIV-1 Quant Dx Assay d. Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0 The grey shaded cells represent those with <85% sensitivity or specificity. Sources: Sacks et al. (42), Vojnov et al. (69) and Vojnov et al. (70). [Transcriber: the job pointed to p6 (index of tables); the table is on p50 (printed p. 35). The table is printed as two blocks, Sensitivity and Specificity; the Specificity block's header is kept as body row 8. Grey shading is not reproduced.]",
      "narratives": {
        "en": "The table shows the sensitivity (upper block) and specificity (lower block), with 95% confidence intervals, of dried blood spot and point-of-care viral load technologies from nine manufacturers for detecting treatment failure at thresholds from 1000 down to 200 copies/ml and at 'detectable'. Grey shading in the original marks values below 85%.",
        "ar": "يعرض الجدول الحساسية (الجزء العلوي) والنوعية (الجزء السفلي)، مع فترات الثقة 95%، لتقنيات اختبار الحمل الفيروسي باستخدام بقع الدم المجففة وفي نقاط الرعاية من تسع جهات مصنعة، في الكشف عن فشل العلاج عند عتبات تتراوح من 1000 إلى 200 نسخة/مل وعند مستوى \"قابل للكشف\". ويشير التظليل الرمادي في الأصل إلى القيم الأقل من 85%.",
        "zh": "本表显示九家制造商的干血斑和即时病毒载量检测技术在1000至200拷贝/毫升各阈值以及\"可检出\"水平下检测治疗失败的敏感性（上半部分）和特异性（下半部分）及其95%置信区间。原表中灰色底纹标示低于85%的数值。",
        "es": "El cuadro muestra la sensibilidad (bloque superior) y la especificidad (bloque inferior), con intervalos de confianza del 95%, de las tecnologías de carga viral en gotas de sangre seca y en el punto de atención de nueve fabricantes para detectar el fracaso terapéutico con umbrales de 1000 a 200 copias/ml y con el umbral «detectable». El sombreado gris del original señala los valores inferiores al 85%.",
        "fr": "Le tableau présente la sensibilité (bloc supérieur) et la spécificité (bloc inférieur), avec leurs intervalles de confiance à 95 %, des technologies de mesure de la charge virale sur papier buvard et au point de service de neuf fabricants pour détecter l’échec thérapeutique à des seuils de 1000 à 200 copies/ml et au seuil « détectable ». L’ombrage gris de l’original signale les valeurs inférieures à 85 %.",
        "ru": "В таблице приведены чувствительность (верхний блок) и специфичность (нижний блок) с 95% доверительными интервалами технологий определения вирусной нагрузки по сухим пятнам крови и по месту оказания помощи девяти производителей для выявления неэффективности лечения при пороговых значениях от 1000 до 200 копий/мл и при уровне «определяемая». Серым цветом в оригинале выделены значения ниже 85%."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table A1",
      "caption": "Table A1. Summary of key normative guidance released and ongoing since 2016, mapped to the corresponding chapters of the consolidated guidelines",
      "pages": [
        73,
        74
      ],
      "columns": [
        {
          "titles": "Chapter",
          "group": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"
        },
        {
          "titles": "Key guidance between 2016 and 2020",
          "group": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"
        },
        {
          "titles": "Latest / upcoming guidance",
          "group": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"
        }
      ],
      "rows": [
        [
          "2. HIV diagnosis",
          "Consolidated guidelines on HIV testing services for a changing epidemic November 2019; Updated recommendations on early infant diagnosis of HIV December 2018",
          "Updated recommendation on using point-of-care infant diagnosis (see subsection 3.1)"
        ],
        [
          "3. Prevention",
          "Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics August 2020; Updated recommendations on post-exposure prophylaxis December 2018",
          "New recommendation on the dapivirine vaginal ring as a prevention option (see subsection 2.1)"
        ],
        [
          "4. HIV treatment and monitoring",
          "Update of recommendations on first- and second-line antiretroviral regimens July 2019; Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy July 2017",
          "Updated recommendation on use of point-of-care viral load testing (see subsection 3.2); Revised treatment monitoring algorithm (see subsection 3.3); New recommendation and updated clinical considerations for TB and HIV in the context of when to start antiretroviral therapy (see section 4.1 and 4.2)"
        ],
        [
          "5. Comorbidities",
          "Guidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV April 2020; Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children March 2018; Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection July 2018; Guidelines on hepatitis B and C testing February 2017",
          "See TB and HIV recommendations above in the context of when to start antiretroviral therapy; Other guidelines processes that are ongoing include: cervical cancer, sexually transmitted infections, physical activity and sedentary behaviour and adolescent mental health"
        ],
        [
          "6. Service delivery",
          "Maintaining and improving quality of care within HIV clinical services July 2019",
          "Ongoing parallel guidelines process to update several recommendations within this chapter"
        ],
        [
          "7. Toxicity, HIV drug resistance, monitoring and evaluation",
          "Consolidated guidelines on person-centred HIV patient monitoring and case surveillance June 2017; Tackling HIV drug resistance: trends, guidelines and global action July 2017; Biobehavioural survey guidelines for populations at risk for HIV September 2017; Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management April 2020",
          "No new recommendations. The consolidated strategic information guidelines are being updated and planned for released in late 2021"
        ],
        [
          "Cross-cutting guidelines",
          "Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations July 2016; Consolidated guideline on sexual and reproductive health and rights of women living with HIV March 2017",
          "Maternal, newborn and child health guidance for women living with HIV"
        ]
      ],
      "notes": "[Transcriber: the job pointed to p6 (index of tables); the table is on pp. 73–74 (printed pp. 58–59). Separate guidance documents within a cell are joined with '; '.]",
      "narratives": {
        "en": "The table maps key WHO normative guidance on HIV released since 2016 to the chapters of the consolidated guidelines on antiretroviral drugs, from HIV diagnosis to cross-cutting guidelines. For each chapter it lists the key guidance published between 2016 and 2020 with dates, and the latest or upcoming guidance.",
        "ar": "يربط الجدول الإرشادات المعيارية الرئيسية لمنظمة الصحة العالمية بشأن فيروس العوز المناعي البشري الصادرة منذ عام 2016 بفصول المبادئ التوجيهية الموحدة بشأن الأدوية المضادة للفيروسات القهقرية، من تشخيص فيروس العوز المناعي البشري إلى المبادئ التوجيهية الشاملة. ويسرد لكل فصل الإرشادات الرئيسية المنشورة بين عامي 2016 و2020 مع تواريخها، والإرشادات الأحدث أو المرتقبة.",
        "zh": "本表将世卫组织自2016年以来发布的艾滋病毒相关主要规范性指导与抗逆转录病毒药物综合指南的各章节相对应，涵盖从艾滋病毒诊断到跨领域指南。对每一章，表中列出2016至2020年间发布的主要指导及其日期，以及最新或即将发布的指导。",
        "es": "El cuadro relaciona las principales orientaciones normativas de la OMS sobre el VIH publicadas desde 2016 con los capítulos de las directrices unificadas sobre el uso de antirretrovirales, desde el diagnóstico del VIH hasta las directrices transversales. Para cada capítulo enumera las orientaciones clave publicadas entre 2016 y 2020, con sus fechas, y las orientaciones más recientes o futuras.",
        "fr": "Le tableau rattache les principales orientations normatives de l’OMS sur le VIH publiées depuis 2016 aux chapitres des lignes directrices unifiées sur l’utilisation des antirétroviraux, du diagnostic du VIH aux lignes directrices transversales. Pour chaque chapitre, il indique les principales orientations publiées entre 2016 et 2020, avec leur date, ainsi que les orientations les plus récentes ou à venir.",
        "ru": "В таблице основные нормативные руководства ВОЗ по ВИЧ, выпущенные с 2016 г., соотнесены с главами сводного руководства по применению антиретровирусных препаратов — от диагностики ВИЧ до межсекторальных руководств. Для каждой главы указаны ключевые руководства, опубликованные в 2016–2020 гг., с датами, а также последние или готовящиеся руководства."
      },
      "csv": "tables/table-a1.csv"
    },
    {
      "label": "Table A2",
      "caption": "Table A2. Technical scoping meetings to inform the clinical guideline update",
      "pages": [
        76
      ],
      "columns": [
        {
          "titles": "Details of scoping meetings held"
        },
        {
          "titles": "Date"
        }
      ],
      "rows": [
        [
          "HIV and TB scoping consultation",
          "2019"
        ],
        [
          "HIV treatment transition and drug sequencing in the context of new antiretroviral drugs (at the Conference on Retroviruses and Opportunistic Infections): think tank https://www.who.int/hiv/pub/meetingreports/think-tank-HIVtreatment-croi2017/en",
          "2017"
        ],
        [
          "Partners synergy meeting",
          "2017"
        ],
        [
          "WHO Meeting on Treatment and Monitoring Optimization of HIV (at the Conference on Retroviruses and Opportunistic Infections) https://www.who.int/hiv/pub/meetingreports/arv-optimization-2018/en",
          "2018"
        ],
        [
          "Technical consultation on infant testing and prophylaxis",
          "2018"
        ],
        [
          "Viral load virtual guideline preparation meetings",
          "2020"
        ],
        [
          "HIVResNet meeting https://www.who.int/publications/i/item/who-hivresnet-2018-meeting-report",
          "2018"
        ],
        [
          "Paediatric Antiretroviral Working Group (PAWG) meeting",
          "Regular meetings are held through the year"
        ]
      ],
      "notes": "[Transcriber: the job pointed to p6 (index of tables); the table is on p76 (printed p. 61).]",
      "narratives": {
        "en": "The table lists the technical scoping meetings held to inform the clinical guideline update, with links to meeting reports where available, and the year each meeting took place.",
        "ar": "يسرد الجدول الاجتماعات التقنية لتحديد النطاق التي عُقدت لدعم تحديث المبادئ التوجيهية السريرية، مع روابط إلى تقارير الاجتماعات حيثما توفرت، والسنة التي عُقد فيها كل اجتماع.",
        "zh": "本表列出为支持临床指南更新而召开的技术范围界定会议，在有会议报告时附上链接，并注明每次会议的年份。",
        "es": "El cuadro enumera las reuniones técnicas de definición del alcance celebradas para fundamentar la actualización de las directrices clínicas, con enlaces a los informes de las reuniones cuando existen, y el año en que se celebró cada reunión.",
        "fr": "Le tableau énumère les réunions techniques de cadrage tenues pour éclairer la mise à jour des lignes directrices cliniques, avec des liens vers les rapports de réunion lorsqu’ils existent, et l’année de chaque réunion.",
        "ru": "В таблице перечислены технические совещания по определению сферы охвата, проведенные для подготовки обновления клинического руководства, со ссылками на отчеты о совещаниях, если они имеются, и годом проведения каждого совещания."
      },
      "csv": "tables/table-a2.csv"
    },
    {
      "label": "Table A3",
      "caption": "Table A3. Summary of PICO questions",
      "pages": [
        77,
        78
      ],
      "columns": [
        {
          "titles": "PICO question"
        },
        {
          "titles": "Summary of systematic review methods"
        }
      ],
      "rows": [
        [
          "PICO 1: Should the dapivirine vaginal ring be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches?",
          "Review type: Systematic review and meta-analysis Review lead: Medical University of South Carolina, USA Search dates: 1 January 2010 to 3 August 2020 Databases searched: PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and EMBASE Number of studies and study design: Five studies were included, comprising data from 10 articles and 8 conference abstracts, including one Phase IIb safety study, two randomized controlled trials and two open-label extension trials."
        ],
        [
          "PICO 2: Should point-of-care nucleic acid testing technologies be used to diagnose HIV among infants and children younger than 18 months of age compared with laboratory-based testing?",
          "Review type: Systematic review and meta-analysis Review group: Global Health Impact Group Team, Atlanta, USA Search dates: January 2014 to August 2020 Databases searched: PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Conference Proceedings Citation Index-Science (CPCI-S) and WHO Global Index Medicus Number of studies and study design: The review identified seven studies, two randomized controlled trials and five cohort studies."
        ],
        [
          "PICO 3: Among people living with HIV who are initiating or receiving ART, is point-of-care molecular HIV viral load monitoring associated with improved management and patient outcomes compared with laboratory-based viral load monitoring?",
          "Review type: Systematic review and meta-analysis Review lead: University of Cape Town, South Africa Search dates: through August 2020 Databases searched: PubMed/MEDLINE, EMBASE, Cochrane Registers of Diagnostic Test Accuracy Studies and Clinical Trials, WHO Global Index Medicus and conference databases (Conference on Retroviruses and Opportunistic Infections, International AIDS Society and African Society for Laboratory Medicine) Number of studies and study design: 35 were included (three systematic reviews reporting on test accuracy, 29 original research reports from 28 studies, and three programmatic reports). Clinical data were reported in six publications and one conference poster, including one randomized clinical trial, two non-randomized studies and four single-cohort studies describing outcomes following point-of-care monitoring."
        ],
        [
          "PICO 4: Should the HIV viral load testing algorithm outlined in the 2016 WHO consolidated guidelines be modified? a) Should the first viral load be done 1 or 3 months after ART initiation (versus 6 months)? b) For people with an elevated viral load, should the repeat viral load be performed earlier (1 month later versus 3–6 months later)? c) Should people receiving efavirenz-based ART with an elevated viral load be switched immediately to second-line ART without a repeat viral load? d) Should the HIV viral load treatment failure threshold be lowered from 1000 copies/ml? If so, to what number of copies/ml?",
          "Review type: Supportive evidence reviews per subquestions Review lead: Global Health Impact Group Team, Atlanta, USA Search dates: January 2005 to June 2020; Conference on Retroviruses and Opportunistic Infections and International AIDS Society and abstracts from 2017 to 2020 Databases searched: a, b, c and d: EMBASE, PubMed/MEDLINE and conference databases (Conference on Retroviruses and Opportunistic Infections and International AIDS Society); d: Cochrane Central Register of Controlled Trials, Conference Proceedings Citation Index-Science and WHO Global Index Medicus Number of studies and study design: The main research question yielded no results following a systematic review approach. The subquestions asked yielded the following: a) Eight randomized controlled trials among adults and two randomized controlled trials among children. An observational study of advanced HIV disease also summarized but not included in the pooled analysis b) Of the 25 studies summarized, 20 were retrospective and five were prospective. Most studies involved adults, one adolescents and two children. c) Of the 31 included studies, 16 studies were relevant to virological failure and/or disease progression, eight studies examined drug resistance (cohort studies) and seven studies looked at HIV transmission. d) Nine national surveys of acquired drug resistance among adults. One systematic review (66 studies included) and one prospective cohort study."
        ],
        [
          "PICO 5: When should ART be initiated for people living with HIV who are receiving (have recently initiated) treatment for TB?",
          "Review type: Systematic review Review team: London School of Hygiene and Tropical Medicine & Liverpool School of Tropical Medicine, United Kingdom Search dates: 1 January 2003 to 12 March 2020 Databases searched: EBSCO Africa-wide information, EBSCO CINAHL Plus, Wiley Cochrane Central Register of Controlled Trials, OvidSP Embase, OvidSP Global Health, World Health Organization Global Index Medicus, OvidSP Medline ALL, and Clarivate Analytics Web of Science Citation Index Number of studies and study design: Ten randomized controlled trials and one unpublished trial were included"
        ],
        [
          "PICO 6: What are the minimum exclusion criteria (TB signs and symptoms) for same-day ART initiation for people newly diagnosed with HIV?",
          "Review type: Systematic review Review team: London School of Hygiene and Tropical Medicine and Liverpool School of Tropical Medicine, United Kingdom Search dates: Varied by database to 12 March 2020 Databases searched: Ebsco Africa-Wide Information; Ebsco CINAHL Plus; Wiley Cochrane Central Register of Controlled Trials, Issue 3 of 12, 2020; OvidSP Embase, 1974 to 2020 March 11; OvidSP Global Health, 1910 to 2020 Week 09; World Health Organization Global Index Medicus; OvidSP Medline ALL, 1946 to March 10, 2020; Clarivate Analytics Web of Science, Science Citation Index Expanded, 1970 to 2020-03-11. Clinical trials registers: Clinical Trials.gov and World Health Organization International Clinical Trials Registry Platform Number of studies and study design: Four observational studies"
        ]
      ],
      "notes": "[Transcriber: the job pointed to p6 (index of tables); the table is on pp. 77–78 (printed pp. 62–63).]",
      "narratives": {
        "en": "The table lists the six PICO questions addressed by the guideline update, and for each summarizes the systematic review methods: review type, review lead or team, search dates, databases searched, and the number and design of included studies.",
        "ar": "يسرد الجدول أسئلة PICO الستة التي تناولها تحديث المبادئ التوجيهية، ويلخص لكل منها أساليب الاستعراض المنهجي: نوع الاستعراض، والجهة أو الفريق المسؤول عنه، وتواريخ البحث، وقواعد البيانات التي جرى البحث فيها، وعدد الدراسات المشمولة وتصميمها.",
        "zh": "本表列出本次指南更新所涉及的六个PICO问题，并对每个问题概述系统评价方法：评价类型、牵头机构或团队、检索日期、检索的数据库以及纳入研究的数量和设计。",
        "es": "El cuadro enumera las seis preguntas PICO abordadas en la actualización de las directrices y, para cada una, resume los métodos de la revisión sistemática: tipo de revisión, responsable o equipo de la revisión, fechas de búsqueda, bases de datos consultadas, y número y diseño de los estudios incluidos.",
        "fr": "Le tableau présente les six questions PICO traitées par la mise à jour des lignes directrices et, pour chacune, résume les méthodes de la revue systématique : type de revue, responsable ou équipe, dates de recherche, bases de données consultées, ainsi que le nombre et le plan des études incluses.",
        "ru": "В таблице перечислены шесть вопросов PICO, рассмотренных при обновлении руководства, и для каждого кратко описаны методы систематического обзора: тип обзора, ответственная организация или группа, сроки поиска, использованные базы данных, а также число и дизайн включенных исследований."
      },
      "csv": "tables/table-a3.csv"
    },
    {
      "label": "Table A4",
      "caption": "Table A4. Criteria for consideration in evidence-to-decision-making tables",
      "pages": [
        80
      ],
      "columns": [
        {
          "titles": "Domain"
        },
        {
          "titles": "Rationale"
        }
      ],
      "rows": [
        [
          "Certainty of the evidence",
          "This is an assessment of the degree of confidence in the estimate of the effect: that is, the likelihood that the effect will differ substantially from what the research found. “Differ substantially” means a large enough difference that it might affect a decision."
        ],
        [
          "Benefits and risks",
          "When a new recommendation is developed, desirable effects (benefits) need to be weighed against the undesirable effects (risks), considering any previous recommendation or another alternative. The larger the gap or gradient in favour of the benefits over the risks, the more likely that a strong recommendation will be made."
        ],
        [
          "Values of outcomes",
          "This is a judgement of how much the people affected by an intervention or option value each of the outcomes. How much people value outcomes in relation to each other needs to be considered when weighing up the desirable effects of a treatment against the undesirable effects."
        ],
        [
          "Cost and resource implications",
          "How large the requirements are in resource use of the intervention and the alternative. Cost: the value of the resources that are consumed (such as staff time, drugs and use of equipment) as the consequences of an intervention or option. Cost–effectiveness: the cost of a treatment in relation to its effects. Lower costs (monetary, infrastructure, equipment or human resources) or greater cost–effectiveness is more likely to support a strong recommendation."
        ],
        [
          "Equity",
          "The absence of avoidable or remediable health differences among group of people that may be defined socially, economically, demographically or geographically."
        ],
        [
          "Acceptability",
          "How much a treatment or recommendation is accepted by the people who are affected by it or who are implementing it. If the recommendation is likely to be widely accepted or valued highly, it is likely that a strong recommendation will be made. A great deal of variability of strong reasons that the recommended course of action is unlikely to be accepted make a conditional recommendation more likely."
        ],
        [
          "Feasibility",
          "Is it feasible to implement an intervention and sustain it? If an intervention is achievable in a setting where the greatest impact is expected, a strong recommendation is appropriate."
        ]
      ],
      "notes": "[Transcriber: the job pointed to p6 (index of tables); the table is on p80 (printed p. 65).]",
      "narratives": {
        "en": "The table lists the domains considered in the evidence-to-decision-making tables (certainty of the evidence, benefits and risks, values of outcomes, cost and resource implications, equity, acceptability and feasibility) and gives the rationale for each.",
        "ar": "يسرد الجدول المجالات التي يُنظر فيها في جداول الانتقال من البيّنات إلى القرارات (درجة اليقين في البيّنات، والفوائد والمخاطر، وقيم النتائج، والتكاليف والآثار المترتبة على الموارد، والإنصاف، والمقبولية، والجدوى) ويقدم الأساس المنطقي لكل منها.",
        "zh": "本表列出从证据到决策表中考虑的各个领域（证据确定性、获益与风险、结局的价值、成本和资源影响、公平性、可接受性及可行性），并给出每一领域的依据。",
        "es": "El cuadro enumera los ámbitos que se tienen en cuenta en los cuadros de la evidencia a la decisión (certeza de la evidencia, beneficios y riesgos, valores de los resultados, costos e implicaciones en materia de recursos, equidad, aceptabilidad y viabilidad) y expone la justificación de cada uno.",
        "fr": "Le tableau énumère les domaines pris en compte dans les tableaux de passage des données probantes à la décision (degré de certitude des données, bénéfices et risques, valeur accordée aux résultats, coûts et incidences sur les ressources, équité, acceptabilité et faisabilité) et en donne la justification.",
        "ru": "В таблице перечислены области, учитываемые в таблицах перехода от фактических данных к решениям (достоверность фактических данных, польза и риски, ценность исходов, затраты и последствия для ресурсов, справедливость, приемлемость и осуществимость), и приведено обоснование для каждой из них."
      },
      "csv": "tables/table-a4.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 36,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 37,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 2
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 5
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p20); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 35,
      "note": "35 of 37 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-340190"
  }
}
